pentosan polysulfate sodium (elmiron) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Pentosan polysulfate sodium (brand name ELMIRON) is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects and is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. The mechanism of action of pentosan polysulfate sodium in interstitial cystitis is not known but was discovered, that it t binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors.   NCATS

Chemistry

  • SMILES: CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO
  • InChIKey: DJWYOLJPSHDSAL-ROUUACIJSA-N
  • Mol. Mass: 554.73
  • ALogP: -1.63
  • ChEMBL Molecules:
    pentosan polysulfate sodium  
    pantethine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$6.9357 - $9.2911
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

bis(n-pantothenylamidoethyl) disulfide | elmiron | fibrase | hemoclar | lipodel | liponet | obliterol | pantethine | pantethine, 14c-labeled cpd | pantethine, (d)-(+)-isomer | pantetina | panthecin | pantomin | pantosin | pentosan | pentosan polysulfate | pentosan polysulfate sodium | pz68 | sp54 | sp 54 | xylan polysulfate | xylan sulfate | xylofuranan sulfate

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (1)


 

Cystitis, Interstitial (approved 1996)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Bipolar Disorder (Phase 2)

Cystitis, Interstitial (Phase 4)

Diarrhea (Phase 3)

Enteritis (Phase 3)

Hyperlipoproteinemias (Phase 3)

Lower Urinary Tract Symptoms (Phase 2)

Mycobacterium bovis (Phase 2)

Osteoarthritis, Knee (Phase 3)

Prostatitis (Phase 2)

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue